Volume 6 Supplement 1
Immunotherapy – 2074. Tolerability of sublingual immunotherapy with tropical mite allergen vaccines using different dosing schedules in asthmatic children
© Almarales et al; licensee BioMed Central Ltd. 2013
Published: 23 April 2013
Immunotherapy with mite allergens is effective both in rhinitis and asthma. However, injection immunotherapy carries a high risk of systemic adverse events, so, the sublingual route (SLIT) is being used more frequently. Efficacy of SLIT in asthma has been widely studied, however, in Cuba, the therapeutic effect of mite vaccines of Dermatophagoides pteronyssinus (Dp), D.siboney (Ds) and Blomia tropicalis(Bt) has been demonstrated only in adults, but not children. This aim is to determinate adherence and tolerability of SLIT with mite allergen vaccines using different treatment schedules in asthmatic children.
One hundred and twenty children (2 to 15 years) with mild to moderate asthma were selected for each treatment schedule. Three dosing schedules were used: (1) maximum of 3 daily drops; (2): max. 5 drops and (3) max. 10 drops, all by sublingual route. Incremental updosing was used for 3 weeks. A maintenance dose of 2000 BU was used once a week for schedule 1 and twice a week for schedules 2 and 3, during 2 months. Standardized House Dust Mite allergen vaccines of Dermatophagoides pteronyssinus, D. siboney and Blomia tropicalis were employed (VALERGEN, BIOCEN, Cuba).
Adherence to treatment was above 90% for the three schemes with no statistically significant difference (p>0,08) among them. The patients tolerated the different dosing schedules without having to change the planned scheme. Only two patients reported local adverse reactions, classified both as grade I (mild tongue itching without medication).
Summarizing, all children tolerated the three schedules similarly and adherence was high.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.